Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2023 04:25 ET | Source: Curium

Curium Announces Exclusive Distribution Agreement in Switzerland with b.e. Imaging for PYLCLARI™, an Innovative 18F-PSMA Pet Tracer Indicated in Adults with Prostate Cancer

PARIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an exclusive rights agreement with b.e. Imaging, for the distribution...
August 15, 2023 10:50 ET | Source: Curium

Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T

PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
July 28, 2023 06:12 ET | Source: Curium

Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer

PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
July 25, 2023 06:06 ET | Source: Curium

Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe

Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
July 21, 2023 03:30 ET | Source: Curium

Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)

PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical...
May 26, 2023 03:42 ET | Source: Curium

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
May 23, 2023 12:57 ET | Source: Curium

Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.

PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
March 14, 2023 10:46 ET | Source: Curium

Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial

To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
March 02, 2023 07:44 ET | Source: Curium

Innovation and Growing Demand for Nuclear Medicine Drives Curium Expansion and 10-Year Commitment to St. Louis, MO

Renaissance in nuclear medicine to attract top St. Louis talentNorth America Headquarters to call Westport Plaza home for the next 10 yearsOver 100 new jobs in the next 3 years ST. LOUIS, March 02,...
December 21, 2022 10:26 ET | Source: Curium

Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99

PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the successful restarting of the BR2 research reactor in Belgium on 20...